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ABSTRACT 
 
Objectives: Management of SLE is complex and variability in practices exists. Guidelines 
have been developed to help improve the management of SLE patients but there has been 
no formal evaluation of these guidelines. This study aims to compare the scope, quality and 
consistency of clinical practice guidelines on the diagnosis, monitoring and treatment of 
patients with systemic lupus erythematosus (SLE). 
 
Methods: Electronic databases were searched up to April 2014. The Appraisal of Guidelines 
for Research and Evaluation (AGREE) II instrument and textual synthesis was used to 
appraise and compare recommendations. 
 
Results: Nine clinical practice guidelines and five consensus statements were identified, 
which covered seven topics: diagnosis, monitoring, treatment, neuropsychiatric SLE, lupus 
nephritis, anti-phospholipid syndrome and other manifestations of lupus. The methodological 
quality of the guidelines was variable, with the overall mean AGREE II scores ranging from 
31% to 75% out of a maximum 100%. Scores were consistently low for applicability, with 
only one guideline scoring above 50%. There was substantial variability in the treatments 
recommended for class II and V lupus nephritis, the recommended duration of maintenance 
therapy for class III/IV lupus nephritis (from 1 to 4 years), and timing of ophthalmological 
examination for patients on corticosteroids.  
 
Conclusion: Published guidelines on SLE cover a complex area of clinical care but the 
methodological quality, scope and recommendations varied substantially. Collaborative and 
multidisciplinary efforts to develop comprehensive, high-quality evidence-based guidelines 
are needed to promote best treatment and health outcomes for patients with SLE. 
 Page 3 of 28 
  
 
Significance and Innovations: 
 Multiple clinical practice guidelines have been developed in the area of systemic 
lupus erythematosus globally 
 SLE Guidelines vary in scope, methodological rigor and recommendations based on 
poor quality evidence 
 International collaborative multidisciplinary efforts are required for the development of 
high quality guidelines. 
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Introduction 
 
Systemic lupus erythematosus (SLE) is a multi-system disease with a highly variable course. 
Management is complex and involves clinicians across many different specialties with 
important variation in practice apparent across and within specialties evident. For example, 
prescription of anti-malarial drugs and testing for anti-phospholipid antibodies are routine 
among rheumatologists but not among non-rheumatologists[1]. Prescribed doses for 
glucocorticoid regimens also differ across specialties[2]. Monitoring protocols and measures 
of disease activity in patients with nephritis varies among rheumatologists, with those with 
greater than 10 years experience more likely to use qualitative (dipstick) than quantitative 
measures of proteinuria to guide therapy[3]. Significant variation in practice is also seen 
within specialty groups such as paediatric rheumatology[4]. 
 
Clinical practice guidelines are “systematically developed statements to assist practitioner 
and patient decisions about appropriate health care for specific clinical circumstances”[5]. 
They need to be rigorously developed, consistent with the scientific literature, accessible and 
implementable in practice[6, 7]. Given the complexity of and variation in SLE management, 
clinical practice guidelines may support clinical decision-making, improve care, and optimize 
outcomes. This review aims to compare the scope, quality and consistency of clinical 
practice guidelines on the diagnosis, monitoring and treatment of patients with SLE.   
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Materials and Methods: 
Eligibility criteria 
 
Evidence based clinical practice guidelines and consensus statements focused primarily on 
diagnosis, monitoring and management of SLE were included. Non-English language 
publications were excluded due to lack of resource for translation. Laboratory protocols, 
primary research, opinions, previous guideline versions and draft unpublished guidelines 
were excluded.  
 
Search for guidelines and consensus statements  
 
MEDLINE, Embase, PsycINFO and CINAHL were searched from inception to April 2014. 
The search strategies are provided in supplementary data (table S1). We also searched the 
websites of guideline organizations (Guidelines International Network and National Guideline 
Clearinghouse, Intercollegiate Guidelines Network [SIGN], National Institute of Health and 
Care Excellence [NICE]) and professional rheumatology and nephrology societies. The titles 
and abstracts were screened by DJT/AT and those which did not meet the inclusion criteria 
were discarded. Full texts of the remaining citations were obtained and examined for 
eligibility.  
 
Appraisal of guidelines and consensus statements  
 
The quality of the each guideline was appraised using the Appraisal of Guidelines and 
Research and Evaluation (AGREE) II instrument[8]. AGREE II is an internationally validated 
23 item tool involving six domains: scope and purpose, stakeholder involvement, rigor of 
development, clarity and presentation, applicability and editorial independence. Each 
guideline was independently appraised by two authors (DJT and SK) and each item within 
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the six domains was rated on a Likert scale ranging from 1 to 7 (1= ‘strongly disagree’; 7= 
‘strongly agree’). Differences in scores were resolved through discussion until consensus 
was reached. Domain scores were calculated as per the AGREE II user’s manual, where a 
total quality score was obtained for each domain by summing the total items scores. The 
following formula was used to determine domain scores as a percentage of the total 
maximum score possible for that domain.   
  
 
Maximum possible score= highest possible score (7) x number of items x number of 
appraisers (2) 
Minimum possible score= lowest possible score (1) x number of items x number of 
appraisers (2)
 
 
Synthesis of guideline recommendations 
 
Textual descriptive synthesis was performed to analyse the scope, content and consistency 
of recommendations across the guidelines. All text from guidelines were imported into 
HyperRESEARCH software for managing and retrieving textual data. DJT inductively 
identified topics addressed by the guidelines and coded the guideline recommendations into 
the corresponding topic. For each topic, the guideline recommendations were compared to 
identify similarities and differences.   
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Results: 
Search and guideline characteristics 
 
The search yielded 2399 citations. Fourteen were eligible and included (nine clinical practice 
guidelines and five consensus statements (figure 1). The articles were published between 
1999 and 2014, nine from international groups and five from national groups. Eight 
guidelines were published by rheumatology societies or working groups, one guideline was 
published by a nephrology guideline organization, and five guidelines were published by 
multidisciplinary working groups. The characteristics of the guidelines are provided in table 
1. Four (29%) guidelines conducted external peer review and 11 (79%) guidelines included a 
systematic literature review, although the methods of data extraction and synthesis varied 
(supplementary data table S2).  
 
Methodological quality  
 
Table 2 provides a summary of the results of the methodological quality appraisal. The 
domain scores of each guideline are displayed in the supplementary data (table S3). The 
highest scoring domain was scope and purpose 67% (44-89%), the lowest scoring domain 
was applicability 29% (4-67%). 
 
Descriptive synthesis 
 
The seven topics addressed by the guidelines were: diagnosis, monitoring, treatment, 
neuropsychiatric SLE, lupus nephritis, anti-phospholipid syndrome and other organ 
manifestations. The scope of the guidelines varied considerably (supplementary data table 
S4, S5). 
 Page 8 of 28 
  
 
Diagnosis 
 
The American College of Rheumatology (ACR) criteria for classification of patients with 
SLE[9] are widely used as a diagnostic aid. In patients with four of the 11 criteria the 
diagnosis of SLE can be made with 95% specificity and 85% sensitivity[9]. One guideline 
specifically stated that SLE should be suspected in any patient with features affecting two or 
more organ systems listed in the ACR criteria[10]. 
 
Monitoring 
 
Six guidelines provided recommendations on monitoring disease activity, disease damage, 
and quality of life[10-15].  
 
Measuring disease activity with full blood count, serum creatinine and urinalysis[10-12], and 
other tests including : C3/C4, anti-dsDNA, anti-phospholipid, anti-RO/SSA, C-reactive 
protein, anti-C1q, serum albumin, estimated glomerular filtration rate (eGFR) and urinary 
protein/creatinine ratio were recommended[12, 13]. The SLE Disease Activity Index 
(SLEDAI) was the only tool specified for adults[13] and adolescents[15]. 
 
Annual assessment of organ damage was recommended[11, 13, 15], The Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology/ Damage Index 
(SLICC/ACR/SDI) was specified for use in both the adult[13] and paediatric[15] populations.  
 
Quality of life monitoring by clinical interview and/or Visual Analogue Scale 
[11] or Paediatric Quality of Life Inventory Generic Core Scale version 4.0 were 
suggested[15]. 
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Monitoring of drug toxicity was mentioned but no thresholds were provided[10, 11]. The 
National Cancer Institute’s Common Terminology Criteria for Adverse Events version 3.0 
was recommended for use to monitor treatment side effects in paediatric SLE[15]. 
 
Long term monitoring was recommended[10, 14], with 3-6 month assessment for mild 
disease and increased frequency for patients with severe active disease and in 
pregnancy[10]. Patients with non-active SLE and no damage or comorbidity could be 
assessed every 6 to12 months with additional evaluation prior to pregnancy, surgery, 
transplantation, use of oestrogen containing medication or occurrence of a new neurological 
or vascular event[11]. 
  
Recommendations for monitoring comorbidities were presented in three guidelines[11, 12, 
16]. EULAR 2010 stated that all patients with SLE should be assessed for adequate calcium 
intake, vitamin D intake, regular exercise, smoking status and cardiovascular risk factors, 
blood cholesterol, glucose, BMI and blood pressure with no specific parameters 
provided[11]. Ophthalmological examination for patients taking anti-malarial medication 
varied; one guideline recommending annual[16] and another five yearly review[11] (table 3). 
 
The ACR 1999 guideline advocated multidisciplinary monitoring of SLE, involving 
collaboration among primary care physicians, specialists, nurses, pharmacist, families and 
patients[10]. 
 
Treatment 
 
Treatment was covered by five guidelines. Recommendations focused on ensuring long-
term survival, preventing organ damage and improving quality of life by controlling disease 
activity, minimizing comorbidities and drug toxicity[14]. Treatment targets for SLE were 
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defined as remission and prevention of flares[14],  with goals defined through a shared 
decision making process between the patient and clinician[14, 17].   
 
Recommended treatment for constitutional SLE included anti-malarial[10, 12, 14], 
corticosteroids and non-steroidal anti-inflammatory drugs[10, 12]. Appropriate adjunct 
therapy included vitamin D and calcium supplements for preventing osteoporosis in patients 
using corticosteroids, antihypertensive and statins were also recommended[12]. One 
guideline recommended that all patients with SLE should receive education, counselling and 
support, particularly in terms of managing the complexity and unpredictability of the 
disease[10]. Multidisciplinary care involving nephrologists, rheumatologists and other 
appropriate specialists was recommended by two guidelines[12, 14]. 
 
Neuropsychiatric SLE 
 
The diagnostic work-up to identify neuropsychiatric disease for patients with SLE should be 
the same as the general population[12, 18]. The EULAR guideline[18] provided in-depth 
recommendations regarding diagnosis with a diagnostic work-up for acute confusional state 
(cerebrospinal fluid analysis and MRI) and optic neuritis (complete ophthalmological 
evaluation, MRI and visual evoked potentials). One guideline addressed recommended 
evaluating attention, concentration and memory for cognitive impairment[11]. 
  
Treatment was discussed in four guidelines[12, 13, 17, 18]. The use of corticosteroids and 
immunosuppressive therapy in neuropsychiatric SLE of inflammatory origin was 
recommended in both EULAR guidelines[12, 18]. For severe disease such as acute 
confusional state, movement disorders, myelitis, psychosis or peripheral nephropathy 
induction therapy (high dose corticosteroids and IV cyclophosphamide) followed with 
maintenance therapy with less intensive immunosuppression was recommended[18]. 
Manifestations, including cerebrovascular, cognitive dysfunction, seizures and major 
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depression should be managed the same as for the general population with anti-coagulation 
recommended for patients with anti-phospholipid syndrome. Methylprednisone alone or in 
combination with immunosuppression was recommended for optic neuritis[18]. Other 
suggestions included Rituximab for cognitive deficits, psychosis or seizures[13] and 
intravenous immunoglobulin, immunoadsorption or plasmapheresis for refractory disease not 
caused by anti-phospholipid syndrome or atherosclerosis[17]. 
 
Lupus Nephritis 
Twelve guidelines provided recommendations on lupus nephritis in four main areas - 
 
1) Indications for renal biopsy and monitoring: Four guidelines specified indications for first 
renal biopsy (table 3). There was variability in proteinuria thresholds for first renal biopsy, 
some guidelines recommended biopsy when proteinuria was 0.5g/24hr with active urine 
sediment[19-21], in addition another guideline recommended biopsy when proteinuria was 
1g/24hr alone[21]. Monitoring C3/C4, anti-dsDNA, full blood cell count and serum creatinine 
were recommended for nephritis; while other recommendations varied (table 3). 
 
2) Treatment: Recommendations are summarized in Table 4. Class II recommendations 
were classified by range of proteinuria by three guidelines,[16, 19, 22] but not classified by 
one guideline[23]. One guideline did not separate class V by non-nephrotic and nephrotic 
proteinuria and recommended that all class V be treated the same as class III and IV[16], 
unlike four other guidelines[19, 20, 22, 23] which recommended only class V with persistent 
nephrotic proteinuria be treated the same as class III and IV. 
 
There were inconsistencies in recommendations for class III and IV induction and 
maintenance therapy. Three guidelines suggested a change of induction agent if there was a 
failure to respond by six months[12, 16, 20] and two recommended this at three months[21, 
22]. The duration of maintenance therapy varied from one to four years[14, 16, 19, 21, 22]. 
 Page 12 of 28 
  
 
 
Hydroxychloroquine use in all lupus nephritis patients was recommended by five 
guidelines[16, 19-22], though one guideline recommended its use only in mild to moderate 
disease[23]. Seven guidelines[10, 15, 16, 19-22] dealt with adjunct therapy for comorbidities 
for lupus nephritis patients, which included antihypertensives, statins, vitamin D and calcium 
supplementation for bone protection and vaccination recommendations (supplementary data 
table S6).  
 
Four guidelines[15, 16, 19, 21] provided definitions of partial and complete remission of 
lupus nephritis where serum creatinine reduction for complete remission was defined as 
<1.2mg/dl[16] or within 125% of baseline at 6-12 months after induction therapy[21], 
(supplementary data table S7).  
 
3) Reproductive health: Seven guidelines addressed this issue (table 5). EULAR EDTA/ERA 
recommended that pregnancy should be planned in patients with inactive lupus nephritis and 
urinary protein creatinine ratio <50 mg/mmol for the preceding 6 months and preferably a 
glomerular filtration rate (GFR) >50 ml/min[19]. Other guidelines indicated that pregnancy 
should not occur until complete remission of lupus nephritis[20, 22]. 
 
4) Paediatric lupus nephritis: Three guidelines addressed this issue[15, 19, 22]. Two 
guidelines recommended that it should be managed similar to adults[19, 22], with drug 
dosages based on patient size and GFR[22]. Coordinated transition from paediatric to adult 
care recommended[19]. One guideline discussed induction therapy for proliferative lupus 
nephritis, with in-depth corticosteroid and immunosuppressant regimens provided; drug 
toxicity thresholds and monitoring tests for mycophenolate mofetil and mycophenolate 
sodium/acid were also provided[15]. 
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Anti-phospholipid syndrome 
 
The therapeutic goal was prevention of thromboembolic events[14, 17]. Low-dose aspirin 
was recommended as primary prevention for thrombosis[12, 19], preeclampsia and 
pregnancy loss[12, 19, 21, 22] and associated nephropathy[19, 21], while in nephropathy 
anti-malarial and/or antiplatelet/anticoagulation therapy could be considered[19], with INR of 
2-3[22]. 
 
Long-term anticoagulation for secondary prevention of recurrent stroke,[19] or thrombosis 
was recommended[12, 16]. Intensive immunomodulatory therapy (high dose glucocorticoids, 
IV immungloublins, plasmapheresis) or B cell depletion (rituximab or apheresis) were 
suggested for catastrophic anti-phospholipid syndrome[17]. 
 
Other manifestations of SLE 
 
Three guidelines provided recommendations regarding other organ manifestations of 
SLE[13, 16, 22]. Lupus arthritis standard of care included corticosteroids, anti-malarial drugs, 
azathioprine and methotrexate[13, 17]. For refractory disease, mycophenolate mofetil as well 
as rituximab were suggested[13, 17]. Anti-IL-1 and anti-TNF antagonists were not 
recommended in these patients[17].  
 
The standard of care for haematological manifestations of SLE included corticosteroids and 
azathioprine, mycophenolate or cyclophosphamide[17],  with rituximab in refractory 
disease[13, 17].  Plasma exchange[18, 23] or immunoadsorption were mentioned[17]. as 
was splenectomy in disease refractory to drug therapy.[17]    
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Discussion 
 
The variability in published guidelines for SLE was substantial, particularly in terms of scope 
and methodological rigor. Many recommendations were consistent but major discrepancies 
were observed for specific clinical situations, particularly proteinuria thresholds indicating 
renal biopsy, treatment of class II and V nephritis and duration of maintenance therapy.  
 
Guideline scope varied broadly, ranging from the complete management of SLE to off label 
medication use. Diagnosis of SLE was sparsely covered by guidelines and perhaps this is 
because it remains a challenging area due to the wide differential diagnoses, lack of 
evidence on the signs, symptoms and biomarkers for SLE and a lack of consensus[24-26]. 
Guidelines rarely discussed the treatment goal of complete and/or partial remission, which 
are frequently reported in randomized control trials of treatment for lupus nephritis despite 
there being no standardized criteria[27]. 
 
Although most guideline recommendations were formed on the basis of a systematic 
literature review, there were important differences in the approach to evidence appraisal and 
grading of recommendations. Guideline applicability was generally poor using the AGREE II 
instrument. For example the target clinical context and patient population were often not 
specified. Also, potential barriers to guideline implementation were not identified in most 
guidelines. To assess barriers, we suggest using the National Institute for Clinical Studies 
barrier tool[28], or Barriers identification and Mitigation tool[29]. Furthermore, criteria and 
frequency for auditing should be provided, for example, lupus nephritis guidelines could 
suggest collecting data on the indication for renal biopsy for on-going audit. Well-designed, 
focused guideline implementation projects with active involvement from guideline 
organizations are widely advocated[30]. Mold et al. 2007 explored adherence to national 
guidelines on asthma using multifaceted interventions in a cluster randomized trial, which 
showed facilitation of the guideline by an independent source improved adherence to 
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recommendations compared to passive facilitation, by the provision of education and 
performance feedback alone[31]. 
 
Improving guideline applicability could also be achieved by the active involvement of patient 
and caregivers in their development, which has been widely advocated[32-34], yet only one 
guideline addressed stakeholder involvement by specifically involving patients in guideline 
development. Active consumer engagement can be facilitated by involving more than one 
consumer in working groups or conducting stakeholder input exercises to elicit consumers’ 
preferences and priorities[35], and this  has been successfully conducted for developing 
guidelines addressing other specialties including chronic kidney disease[36]. 
 
The recommendations on the diagnosis, monitoring and treatment for lupus nephritis varied 
across guidelines and this could be due to the different populations included. For example, 
one guideline focused on the treatment of paediatric patients[15], and another guideline 
focused on treatment of adult Asian patients[23]. These discrepancies were more apparent 
in areas with low quality evidence and were thus based on expert opinion and consensus, 
for example treatment of class II and V lupus nephritis. In some areas evidence was not 
included in guideline recommendations, for example intravenous cyclophosphamide use in 
induction therapy. A recent Cochrane review suggested that mycophenolate mofetil and 
corticosteroids have the same efficacy at inducing remission and a better side effect profile 
compared to cyclophosphamide and corticosteroids[37]. Two guidelines were published after 
this review[15, 23] but specific therapies for lupus nephritis induction was not covered by 
one[14], while the other recommended corticosteroid and either mycophenolate mofetil or 
cyclophosphamide induction therapy[23]. 
 
Some important areas of treatment were not covered in guidelines, such as non-adherence. 
Rates of non-adherence in SLE have been reported as high as 76%[38] and are associated 
with a higher risk of flare, morbidity, hospitalization and poor renal outcome[39]. Non-
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adherence to therapy as a cause of treatment failure is commonly seen in clinical 
practice[28] and may affect therapeutic decisions. Addressing the issue of adherence is 
likely to be an important part of optimizing outcomes and a number of trials are underway 
examining a mean of measuring adherence and will help inform future guidelines[40], while 
further studies are required to identify appropriate interventions for adherence in chronic 
disease[41].  
 
This study is the first to systematically review the quality of clinical practice guidelines on 
SLE diagnosis, monitoring and treatment. However, our study has limitations. The 
assessment of the guidelines is based on the reporting by guideline developers and the 
exclusion of non-English guidelines may limit the generalizability of the findings to other 
settings. Overall there is significant variability in existing guidelines for the management of 
SLE. Some of the variation is explained by the paucity of evidence in areas such as 
biomarkers, signs and symptoms for the monitoring and diagnosis of SLE, studies to identify 
the lowest ‘safe’ dose of corticosteroid and the duration of maintenance therapy for patients 
with nephritis. Furthermore evidence-based criterion for diagnosis, SLE flare, SLE remission 
need to be better defined and means of monitoring adherence would be a beneficial addition 
to guidelines.  
 
Clearly a great deal of work has been done in developing the identified guidelines but to 
avoid duplication of effort in the future we recommend that international collaborative 
multidisciplinary efforts are undertaken to ensure the development of comprehensive, high 
quality evidence-based guidelines and improve the treatment and health of patients with 
SLE.  
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Table 1: Characteristics of included guidelines 
Guideline 
Organization/ 
Society 
Guideline Name/s Year of 
Publication 
Target Users Work Group 
Specialties 
Guideline 
Review 
Methods 
Support 
Evidence 
Base 
Level of 
Evidence * 
Grade of 
recommendation † 
EULAR [12] EULAR recommendations 
for the management of SLE  
2008 Not stated Rheumatology 
Immunology 
Nephrology    
Epidemiology  
Review 
(unclear if 
external)  
Editorial 
Team  
Systematic 
review and 
expert opinion 
+ + 
 
EULAR [18] EULAR recommendations 
for the management of 
neuropsychiatric SLE  
2010 Not clear Rheumatology 
Neurology 
Radiology 
Immunology 
Epidemiology 
External peer 
review 
Editorial 
Team  
Systematic 
review 
+ 
 
+ 
 
EULAR [11] EULAR recommendations 
for monitoring patients with 
SLE   
2010 Not clear Rheumatology 
General Medicine  
Dermatology  
Nephrology 
Immunology   
External peer 
review 
Editorial 
Team 
Systematic 
review 
+ 
 
+ 
 
EULAR/ERA-
EDTA [19] 
 (EULAR/ERA-EDTA) 
recommendations for the 
management of lupus 
nephritis 
2012 Not clear Rheumatology 
Nephrology 
Pathology          
General medicine 
Neurology  
External peer 
review 
Editorial 
Team  
Systematic 
review 
+ 
 
+ 
 
ACR [10] Guidelines for referral and 
management of SLE in 
adults  
1999 Primary care 
physicians 
Rheumatology Reviewed by 
primary care 
physicians 
Not stated Available 
evidence‡ and 
expert opinion 
— — 
ACR [20] ACR Guidelines for 
screening, treatment and 
management of lupus 
nephritis 
2012 Physicians 
managing lupus 
nephritis 
patients 
Rheumatology 
Nephrology 
Internal 
Review 
Working 
group 
Systematic 
review and 
expert opinion 
+ 
 
— 
KDIGO [22] KDIGO Guideline for 
Glomerulonephritis. Chapter 
12: Lupus Nephritis 
2012 Nephrologists Nephrology External peer 
review 
Evidence 
Review 
Team 
Systematic 
review 
+ 
 
+ 
 
SER [13] SER consensus statement 
on the use of Biologic 
Therapy for SLE 
2013 Clinicians 
involved in 
treatment of 
SLE patients  
Rheumatology   Not stated SER 
Research 
Unit   
Systematic 
review  
+ 
 
+ 
 
SEMI and SEN 
[16] 
Diagnosis and treatment of 
lupus nephritis. Consensus 
document  
2012 Not clear Rheumatology 
Nephrology  
Not stated Not stated Systematic 
review and 
expert opinion 
+ 
 
+ 
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Guideline 
Organization/ 
Society 
Guideline Name/s Year of 
Publication 
Target Users Work Group 
Specialties 
Guideline 
Review 
Methods 
Support 
Evidence Base Level of 
Evidence * 
Grade of 
recommendation † 
Dutch Working 
Group on SLE 
[21] 
Dutch Guidelines for 
diagnosis and therapy of 
proliferative lupus nephritis 
2012 Not clear Rheumatology 
Nephrology 
Immunology 
Not stated Not stated Systematic 
review and 
expert opinion 
+ 
 
— 
Working group 
of experts on 
SLE/ Aringer et 
al. [17] 
 ‘off-label’ therapeutic 
options for SLE. 
2012 Clinicians 
involved in 
treatment of 
difficult SLE 
Rheumatology  Not stated Not stated Systematic 
review and 
expert opinion 
+ 
 
— 
T-2-T 
international 
task force [14] 
Treat-to-target in systemic 
lupus erythematosus: 
recommendations from an 
international task force 
2014 Those involved 
in care of 
patients with 
SLE 
Rheumatology 
Nephrology 
Immunology 
Dermatology 
Internal medicine 
Patient 
representative 
External peer 
review 
Not stated Systematic 
review and 
expert opinion 
+ + 
ALNN [23] §  Lupus nephritis 
management guidelines, 
perspective from Asia 
2013 Not clear Nephrology 
Rheumatology 
Not stated Not stated Available 
evidence‡ and 
expert opinion 
+ + 
CARRA [15] Consensus treatment plans 
for induction therapy of 
proliferative lupus nephritis 
in juvenile SLE 
2012 Paediatric 
rheumatologists  
Rheumatology Not stated Not stated Systematic 
review and 
expert opinion 
— + 
  
EULAR- European League Against Rheumatism; ERA- European Renal Association; EDTA- European Dialysis and Transplant Association; ACR- American College of Rheumatology; 
KDIGO- Kidney Disease Improving Global Outcomes; SER- Spanish Society of Rheumatology; SEMI- The Spanish Society of Internal Medicine; SEN- Spanish Society of Nephrology;  
T-2-T- Treat-to-target; ALNN- Asian Lupus Nephritis Network CARRA- Childhood Arthritis and Rheumatology Research Alliance 
 
+ = used in guideline recommendations — = not used in guideline recommendations 
*, † Detailed explanation of level of evidence and grade of recommendation in supplementary data (table S2).  
 
‡ Available evidence- Unclear if systematic review completed. 
  
§ ALLN 2013 is also published in Nephrology. Mok, CC, Yap DYH, Navara SV, Liu ZH, Zhao MH, Lu L, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA, Lugue-Lizardo LR, Sumethkul V, Shen 
Nm Chen SL, Chan TM. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology 2014;19(1):11-20. 
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Table 2: Guideline assessment, mean domain scores using AGREE II instrument (n=14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Domain Mean domain score (range)%     Number of guidelines that scored ≥50% 
Scope and purpose 67 (44-89) 12 
Stakeholder involvement  42 (28-78) 4 
Rigor of development 44 (17-83) 7 
Clarity and presentation 64 (33-100) 11 
Applicability  29 (4-67) 1 
Editorial independence  55 (8-92) 8 
Overall mean 50 (31-75) 8 
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Table 3: Guideline recommendations for first renal biopsy and monitoring lupus nephritis 
Guideline Recommendations EULAR [11, 12] 
 
 
EULAR/ERA-EDTA 
[19] 
ACR [10, 20] KDIGO [22] SEMI and SEN [16] Dutch Group [21] 
Indications for first renal biopsy 
Proteinuria  ○ 
 
● 
0.5g/24hr 
● 
1g/24hr 
— ○ 
 
● 
0.5g/24hr 
Active urine sediment (haematuria and/or 
cellular casts) 
○ 
 
 
● 
+ proteinuria 
 
●  
+ proteinuria  
0.5g/24 hr. 
— ○ ● 
+ proteinuria 
Serum creatinine (inexplicable elevation)  ○ 
 
— ○ 
 
— — ● 
>30% elevation 
Kidney function (abnormal renal function) — ● — — ● ● 
Histological classification system 
(ISN/RPS* 2003) 
— ● 
 
● 
 
— ● 
 
● 
Monitoring 
Frequency of visits (3-6 monthly monitoring 
& increased for active disease) 
— ● 
 
● — ● 
 
— 
Blood pressure (mmHg) ○ ○ ○ — ○ ●<130/80 
Body weight (BMI or waist circumference) ○ ○ — — — ● 25 
Kidney function (eGFR) ● ● — — ● — 
Proteinuria  ● ● ● — ● — 
Urinalysis  ● ● ● — ● — 
Immunological tests (C3/C4 Anti-dsDNA) ● ●  
+anti-phospholipid 
● 
 
— ● 
+ yearly anti-
Ro/La/RNP/SM/C1q 
— 
Other blood tests (full blood count, serum 
creatinine) 
— ● 
+ serum albumin 
● 
+ alkaline 
phosphatase, Na
2+
, 
K
+
 Ca
2+
P
3-
, 
cholesterol 
— ● 
+blood glucose, 
serum urea/albumin 
anticoagulant PTH, 
25(OH)D3 
— 
Lipid profile — ● — — ● — 
Initial renal ultrasound  — — — — ● — 
Ophthalmological examination (patients on 
anti-malaria therapy) 
● 
5 yearly 
— — — ● 
Yearly 
— 
Indications for repeat renal biopsy 
Proteinuria  — ● 
<50% reduction 
— ● 
<50% reduction 
○ 
 
— 
Serum Creatinine (rising creatinine) — — — ● — — 
Worsening GFR — ● ● — — — 
Relapse of disease (if change in disease 
suspected) 
— ● 
 
— ● — — 
Other — No response to 
treatment  
  
No response to 
treatment    
or/and deteriorating 
renal function  
Worsening disease 
or no remission 
after 12 months 
 
No response to 
treatment  
Only if it will have a 
therapeutic benefit  
○= recommended without dosage/criteria ●= recommended   — = no recommendation    
*(ISN/RPS)= International Society of Nephrology/Renal Pathology Society     
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Table 4: Guideline recommendations for treatment of lupus nephritis 
Guideline Treatment 
Recommendations 
 
EULAR 
[11, 12] 
EULAR/ 
ERA-
EDTA [19] 
ACR  
[10, 20]  
KDIGO 
[22] 
SEMI and 
SEN [16] 
Dutch 
Group 
[21]  
Aringer 
et al [17] 
ALNN* 
[23] 
CARRA†  
[15] 
Class I lupus nephritis 
Treat to extra renal  — — — ● ● — — — — 
Class II lupus nephritis 
Treat to proteinuria — ● 
Yes 
— ● 
Yes 
● 
Yes 
— — ● 
No 
— 
Proteinuria <1g/d 
Treat to extra renal  — — — ● ● — — — — 
Proteinuria>1-2g/d 
CS (mg/kg/d) — ● 
0.25-0.5 
— — ● 
0.5 
— — ○ — 
AZA (mg/kg/d) or — ● 
1-2 
— — ○ 
 
— — ○ — 
MMF (mg/kg/d) — — — — ○ 
 
— — ○ — 
Proteinuria >3g/d 
CS(mg/kg/d) for 1-4 
months 
— — — ● 
1 
— — — ○ — 
CNI — — — ● — — — — — 
Class III and IV lupus nephritis 
Induction therapy 
Pulsed MPD (g/d) & — ● 
0.5-0.75 
● 
0.5-1.0 
— ● 
0.25-1.0 
● 
0.75 
— ● 
0.5-1  
● 
0.3-1 
CS(mg/kg/d) & ○ ● 
0.5 
● 
0.5-1 
○ ● 
 0.5-1 
<60mg/d 
● 
0.5-1 
<60mg/d 
● 
0.5 
● 
0.5-0.6‡    
●§
 
IV CYC (dose) or  ○ ● 
3g over 3 
months 
● 
‘Euro 
lupus’‖ or 
‘NIH’¶
 
○ ● 
‘Euro 
 Lupus’‖ 
● 
‘Euro 
lupus’‖ 
● 
‘Euro 
lupus’‖ 
○ ● 
‘NIH’¶
 
MMF(g/d) or ○ ● 
3 
● 
2-3 
○ ● 
1 to 2-2.5 in 
2 wks. 
● 
1 to 3 in 
2 wks. 
○ ● 
1.5-2 
● 
<3 
MPA (g/d) or — ● 
equivalent 
to MMF 
● 
1.44-2.16 
— ● 
 0.72 to 1.44-
1.88 in 2 
wks. 
— — — ● 
<1.08 
AZA(mg/kg/d) — ● 
2 
— — — — — — — 
Tapering of CS (mg/d)  — ● 
≤10 by 4-6 
months 
○ 
 
— — ● 
5-7.5 by 30 
months 
— ● 
< 20 by 3 
months, 
≤7.5 by 6 
months 
● 
10-20 by 
6 months 
IV CYC for adverse 
prognosis (IV g/m
2
 , 
Oral mg/kg/d)  
— ●  
0.75-1, 
2-2.5 
— — ● 
0.75, —  
— — ○ — 
CNI when MMF and 
CYC contraindicated 
— — — — — — — ○ 
 
— 
Review treatment 
(months) 
● 
6  
— ● 
6  
● 
3 
● 
6  
● 
3  
— — ● 
3 
Maintenance therapy 
CS (mg/d ) & — ● 
5-7.5 
— ● 
<10 
  ● 
<10 
○ — — — 
MMF (g/d) or — ○ ○ ● 
1-2 
● 
1.5-2 
○ — — — 
MPA (g/d) or  — — — — ● 
1.1 -1.4 
— — — — 
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Guideline Treatment 
Recommendations 
 
EULAR  
[11, 12] 
EULAR/ 
ERA-
EDTA [19] 
ACR  
[10, 20] 
KDIGO 
[22] 
SEMI and 
SEN [16] 
Dutch 
Group 
[21]  
Aringer 
et al. 
[17]  
ALNN* 
[23] 
CARRA† 
[15]
 
AZA (mg/kg/d) or  — ● 
2 
○ ● 
1.5- 2.5 
● 
1.5-2 
○ ○ — — 
Duration of therapy 
(years) 
— ● 
3  
— ● 
1  
● 
2  
● 
4 
— — — 
Class V lupus nephritis 
+ non-nephrotic proteinuria 
Treat to extra renal  — — — ● — — — — — 
Same as class III & IV — — — — ● — — — — 
+ CNI or AZA — — — — ● — — — — 
+ persistent nephrotic proteinuria 
Induction therapy 
Same as class III & IV — ● ● ● ● — — ● — 
+ CNI or AZA — — — ● ● — — ● — 
Maintenance therapy 
Same as class III & IV — ● ● — ● — — ● — 
CNI — — — — — — — ● — 
Class VI lupus nephritis 
Treat to extra renal  — — — ● ● — — — — 
Stage 5 CKD 
(<30ml/min GFR) 
prepare for RRT 
— — — — ● — — — — 
Difficult disease 
Relapsing lupus nephritis 
Same induction/ 
maintenance therapy 
— — — ● ● — — — — 
CYC toxicity, switch 
immunosuppressant 
— — — ● ● — — — — 
Non-responders 
Switch 
immunosuppressant  & 
— ● ● ● ● ● — — — 
Pulsed MPDs (same as 
induction therapy) & 
— — ● — — ● — — — 
CS (1mg/kg/d max 
60mg/d) 
— — — — — ● — — — 
Alternative treatments  
rituximab  — ● ● ● ● ● ● — — 
CNI   — — — ● ● ● ● — — 
Immunoglobulin — — — ● ● — — — — 
Immunoadsorption — — — — — — ● — — 
TNF blockade  — — — — — — ● — — 
All classes of lupus nephritis 
hydroxychloroquine  
(dose) 
— ○ ○ ● 
≤6-6.5 
mg/kg/d 
ideal wt. 
○ ● 
200-
400mg 
— ● 
 Only 
class II 
— 
Ethnicity dependent  
dosing  
— — ● 
MMF, 
CYC 
— ●  
MMF, CYC 
— — ● 
All 
— 
 
○= recommended without dosage/criteria ●= recommended    — = no recommendation 
CS= corticosteroid, AZA= azathioprine, MMF= mycophenolate mofetil, CNI= calcineurin inhibitors, MPD= methylprednisolone 
CYC=cyclophosphamide, MPA= mycophenplolic acid/ sodium 
 
*
 
ALNN recommendations are for adult Asian lupus nephritis patients 
† CARRA recommendations on paediatric lupus nephritis 
‡ 0.8 mg/kg/day prednisone when not used with IV MPD 
§ See reference for CS dosages, CS regimen can be primarily oral, primarily IV or mixed oral/IV 
‖ Euro lupus IV CYC dose= 0.5 g/m
2
 fortnightly for a total of 6 doses (3 months) 
¶ NIH IV CYC dose= 0.5-1 g/m
2
 monthly for 6 months 
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Table 5: Guideline recommendations for pregnancy and lupus nephritis 
 
●= recommended    — = no recommendation 
* CARRA recommendations on paediatric lupus nephritis 
  
Guideline Recommendations EULAR 
[11, 13] 
EULAR/ 
ERA-
EDTA [19] 
ACR  
[10, 20] 
KDIGO 
[22] 
SEMI and 
SEN [16] 
Dutch 
Group 
[21]  
CARRA*
 
[15] 
Reproductive health & lupus nephritis (LN) 
Fertility  
MMF/MPA recommended over CYC  
— — ● — — — — 
Oestrogen based contraceptives not 
recommended in active LN  
— — — ● ● — — 
Delaying pregnancy until LN remission 
— — ● ● — — — 
Gonadotropin for ovarian protection 
— — — — — — ● 
Pregnancy and SLE 
Monitoring  
Multi-disciplinary monitoring  
— — — — ● — — 
Close/monthly monitoring  
● — — — ● — — 
Pregnancy avoidance in ESKD 
— — — — ● — — 
Recommended treatments 
CS (low dose) 
● ● ● ● — — — 
AZA 
● ● ● ● — — — 
Hydroxychloroquine 
● ● ● ● — — — 
CNI 
— ● — — — — — 
Low dose aspirin 
● — — ● ● ● — 
Treatments not recommended 
MMF/MPA 
● — ● ● — — — 
CYC 
● — ● — — — — 
ACEs/ARBs 
— — — ● ● — — 
Methotrexate 
● ● ● — — — — 
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Figure legends: 
 
Figure 1: Search results 
* Guideline organizations; SIGN, NICE and professional rheumatology and nephrology society websites.  
